Teknova Reports Second Quarter 2025 Financial Results
Teknova (Nasdaq: TKNO) reported strong Q2 2025 financial results with total revenue of $10.3 million, marking a 7% increase from Q2 2024. The company achieved four consecutive quarters of year-over-year growth and reaffirmed its 2025 revenue guidance of $39-42 million.
Key financial metrics include: Lab Essentials revenue of $7.8 million (up 2%), Clinical Solutions revenue of $2.1 million (up 32%), and improved gross margin of 38.7% compared to 29.2% in Q2 2024. The company reported a net loss of $3.6 million ($0.07 per share), showing improvement from the $5.4 million loss in Q2 2024. Cash position stands at $24.0 million with total borrowings of $13.2 million.
Teknova (Nasdaq: TKNO) ha riportato solidi risultati finanziari nel secondo trimestre 2025 con un fatturato totale di 10,3 milioni di dollari, segnando un aumento del 7% rispetto al secondo trimestre 2024. L'azienda ha registrato quattro trimestri consecutivi di crescita anno su anno e ha confermato la previsione di ricavi per il 2025 compresa tra 39 e 42 milioni di dollari.
I principali indicatori finanziari includono: un fatturato da Lab Essentials di 7,8 milioni di dollari (in crescita del 2%), un fatturato da Clinical Solutions di 2,1 milioni di dollari (in aumento del 32%) e un margine lordo migliorato al 38,7% rispetto al 29,2% del secondo trimestre 2024. L'azienda ha riportato una perdita netta di 3,6 milioni di dollari (0,07 dollari per azione), migliorando rispetto alla perdita di 5,4 milioni del secondo trimestre 2024. La posizione di cassa è pari a 24,0 milioni di dollari con un indebitamento totale di 13,2 milioni di dollari.
Teknova (Nasdaq: TKNO) reportó sólidos resultados financieros en el segundo trimestre de 2025 con un ingreso total de 10,3 millones de dólares, lo que representa un aumento del 7% respecto al segundo trimestre de 2024. La compañía logró cuatro trimestres consecutivos de crecimiento interanual y reafirmó su previsión de ingresos para 2025 entre 39 y 42 millones de dólares.
Los principales indicadores financieros incluyen: ingresos de Lab Essentials de 7,8 millones de dólares (un aumento del 2%), ingresos de Clinical Solutions de 2,1 millones de dólares (un incremento del 32%) y un margen bruto mejorado del 38,7% frente al 29,2% del segundo trimestre de 2024. La compañía reportó una pérdida neta de 3,6 millones de dólares (0,07 dólares por acción), mostrando una mejora respecto a la pérdida de 5,4 millones en el segundo trimestre de 2024. La posición de caja es de 24,0 millones de dólares con un endeudamiento total de 13,2 millones de dólares.
Teknova (나스닥: TKNO)는 2025년 2분기에 총 매출 1,030만 달러를 기록하며 2024년 2분기 대비 7% 증가한 강력한 재무 실적을 보고했습니다. 회사는 연속 4분기 연간 성장을 달성했으며 2025년 매출 가이던스를 3,900만~4,200만 달러로 재확인했습니다.
주요 재무 지표로는 Lab Essentials 매출 780만 달러(2% 증가), Clinical Solutions 매출 210만 달러(32% 증가), 그리고 2024년 2분기 29.2%에서 개선된 38.7%의 총이익률이 포함됩니다. 순손실은 360만 달러(주당 0.07달러)로 2024년 2분기 540만 달러 손실에서 개선되었습니다. 현금 보유액은 2,400만 달러이며 총 차입금은 1,320만 달러입니다.
Teknova (Nasdaq : TKNO) a annoncé de solides résultats financiers pour le deuxième trimestre 2025 avec un chiffre d'affaires total de 10,3 millions de dollars, soit une hausse de 7 % par rapport au deuxième trimestre 2024. La société a enregistré quatre trimestres consécutifs de croissance annuelle et a confirmé ses prévisions de chiffre d'affaires pour 2025, comprises entre 39 et 42 millions de dollars.
Les principaux indicateurs financiers incluent : un chiffre d'affaires Lab Essentials de 7,8 millions de dollars (en hausse de 2 %), un chiffre d'affaires Clinical Solutions de 2,1 millions de dollars (en hausse de 32 %) et une marge brute améliorée de 38,7 % contre 29,2 % au deuxième trimestre 2024. La société a enregistré une perte nette de 3,6 millions de dollars (0,07 dollar par action), en amélioration par rapport à la perte de 5,4 millions au deuxième trimestre 2024. La trésorerie s'élève à 24,0 millions de dollars avec un endettement total de 13,2 millions de dollars.
Teknova (Nasdaq: TKNO) meldete starke Finanzergebnisse für das zweite Quartal 2025 mit einem Gesamtumsatz von 10,3 Millionen US-Dollar, was einer Steigerung von 7 % gegenüber dem zweiten Quartal 2024 entspricht. Das Unternehmen erzielte vier aufeinanderfolgende Quartale mit Wachstum im Jahresvergleich und bestätigte seine Umsatzprognose für 2025 von 39 bis 42 Millionen US-Dollar.
Zu den wichtigsten Finanzkennzahlen gehören: Lab Essentials-Umsatz von 7,8 Millionen US-Dollar (plus 2 %), Clinical Solutions-Umsatz von 2,1 Millionen US-Dollar (plus 32 %) sowie eine verbesserte Bruttomarge von 38,7 % im Vergleich zu 29,2 % im zweiten Quartal 2024. Das Unternehmen verzeichnete einen Nettoverlust von 3,6 Millionen US-Dollar (0,07 US-Dollar pro Aktie), was eine Verbesserung gegenüber dem Verlust von 5,4 Millionen US-Dollar im zweiten Quartal 2024 darstellt. Die Cash-Position beträgt 24,0 Millionen US-Dollar bei Gesamtverbindlichkeiten von 13,2 Millionen US-Dollar.
- Revenue growth of 7% year-over-year to $10.3 million
- Clinical Solutions revenue increased 32% to $2.1 million
- Gross margin improved significantly to 38.7% from 29.2%
- Operating expenses decreased by $0.5 million
- Net loss improved to $3.6 million from $5.4 million year-over-year
- Adjusted EBITDA improved to -$0.8 million from -$2.6 million
- Continued net loss of $3.6 million in Q2 2025
- Negative free cash flow of $2.3 million
- Lab Essentials segment showed minimal growth of only 2%
- Total borrowings of $13.2 million against $24.0 million cash position
Insights
Teknova showed modest 7% revenue growth while significantly improving margins and cutting losses, reaffirming full-year guidance despite sector headwinds.
Teknova's Q2 2025 results demonstrate cautious improvement in a challenging market environment. The company posted
The most significant bright spot appears in profitability metrics. Gross margin expanded substantially to
The segment breakdown reveals divergent performance: Lab Essentials (core business) grew modestly at
Cash utilization is showing discipline with free cash outflow improving to
Management's reiterated 2025 guidance of
Second quarter 2025 total revenue was
Achieves four consecutive quarters of year-over-year revenue growth
Company reaffirms 2025 revenue guidance of
HOLLISTER, Calif., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova” or the “Company”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced financial results for the second quarter ended June 30, 2025.
“Despite continued uncertainty in the macroenvironment, we delivered another strong quarter of results, with improvements in both the top and bottom lines,” said Stephen Gunstream, President and Chief Executive Officer at Teknova. “We continue to believe that the investments we’ve made in our operational and commercial infrastructure, combined with our diverse product portfolio and customer base, position Teknova for sustainable, above-market growth over the long-term.”
Matt Lowell, Teknova’s Chief Financial Officer, added, “Compared to 2024, we delivered
Corporate and Financial Updates
- Second quarter 2025 total revenue of
$10.3 million , up7% from the second quarter 2024 - Revenue was up year-over-year for each of the past four consecutive quarters
- Total cash and short-term investments were
$24.0 million and total borrowings were$13.2 million at the end of the second quarter 2025
Revenue for the Second Quarter 2025
| For the Three Months Ended June 30, | For the Six Months Ended June 30, | |||||||||||||||
| (Dollars in thousands) | 2025 | 2024 | 2025 | 2024 | ||||||||||||
| Lab Essentials | $ | 7,792 | $ | 7,638 | $ | 15,909 | $ | 14,904 | ||||||||
| Clinical Solutions | 2,060 | 1,565 | 3,222 | 3,283 | ||||||||||||
| Other | 435 | 411 | 951 | 717 | ||||||||||||
| Total revenue | $ | 10,287 | $ | 9,614 | $ | 20,082 | $ | 18,904 | ||||||||
Second Quarter 2025 Financial Results
Total revenue for the second quarter 2025 was
Gross profit for the second quarter 2025 was
Operating expenses for the second quarter 2025 were
Net loss for the second quarter 2025 was
Adjusted EBITDA for the second quarter 2025 was negative
Reiterates 2025 Outlook
Teknova reiterates its fiscal 2025 outlook for revenue and free cash outflow. The Company continues to anticipate total revenue of
Conference Call and Webcast
Teknova will host a webcast and conference call on Thursday, August 7, 2025, beginning at 5:00 p.m. Eastern Time. To access the live webcast, listeners can log onto the call from the Investor Relations section of the Teknova website or by using this link. If you would like to participate in the call, please register for the webcast here to receive a unique PIN number and dial-in information. The webcast will be available for replay on the Company’s website approximately two hours after the event.
About Teknova
Teknova makes solutions possible. Since 1996, Teknova has been innovating the manufacture of critical reagents for the life sciences industry to accelerate the discovery and development of novel breakthroughs that will help people live longer, healthier lives. We offer fully customizable solutions for every stage of the workflow, supporting industry leaders in molecular diagnostics, synthetic biology, and emerging therapeutic modalities. Our fast turnaround of high-quality agar plates, microbial culture and cryopreservation media, buffers and reagents, and water helps our customers scale seamlessly from RUO to GMP. Headquartered in Hollister, California, with over 180,000 square feet of state-of-the-art facilities, Teknova’s modular manufacturing platform was designed by our team of scientists, engineers, and quality control experts to efficiently produce the foundational ingredients for the discovery and commercialization of next-generation therapies.
Non-GAAP Financial Measures
This press release contains financial measures that have not been calculated in accordance with U.S. generally accepted accounting principles (GAAP). Teknova uses the following non-GAAP financial measures in assessing the performance of its business and the effectiveness of its business strategies: (a) Adjusted EBITDA and (b) Free Cash Flow.
Teknova defines Adjusted EBITDA as net loss adjusted for interest income (expense), net, provision for (benefit from) income taxes, depreciation expense, amortization of intangible assets, and stock-based compensation expense. Adjusted EBITDA reflects further adjustments to eliminate the impact of certain items, including certain non-cash and other items that Teknova does not consider representative of its ongoing operating performance.
Teknova continues to define Free Cash Flow as cash used in operating activities plus purchases of property, plant, and equipment.
Teknova provides Adjusted EBITDA and Free Cash Flow in this press release because Teknova believes that analysts, investors, and other interested parties frequently use these measures to evaluate companies in Teknova’s industry and that such measures facilitate comparisons on a consistent basis across reporting periods. Teknova also believes such measures are helpful in highlighting trends in Teknova’s operating results because they exclude items that are not indicative of Teknova’s core operating performance. Investors should consider non-GAAP financial measures in addition to, and not as a substitute for, or as superior to, measures of financial performance prepared in accordance with GAAP. The non-GAAP financial measures presented by Teknova may be different from the non-GAAP financial measures used by other companies.
A full reconciliation of these non-GAAP measures to the most comparable GAAP measures is included at the end of this release.
Forward-Looking Statements
Statements in this press release about future expectations, plans, and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements.” These statements include, but are not limited to, statements relating to Teknova’s anticipated total revenue, including expectations for 2025 revenue and free cash outflow guidance, and other statements about Teknova’s business prospects, including about Teknova’s profitability, strategy of managing operating expenses, and long-term growth strategy. The words, without limitation, “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would,” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these or similar identifying words. These forward-looking statements are based on management’s current expectations and beliefs and are subject to risks and uncertainties, all of which are difficult to predict and many of which are beyond Teknova’s control and could cause actual results to differ materially and adversely from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, demand for Teknova’s products (including the potential delay to or pausing of customer orders); Teknova’s assessment of fundamental indicators of future demand across its target customer base; Teknova’s cash flows and revenue growth rate; Teknova’s supply chain, sourcing, manufacturing, and warehousing; inventory management; risks related to global economic and marketplace uncertainties, including those related to the conflicts in Ukraine and the Middle East; reliance on a limited number of customers for a high percentage of Teknova’s revenue; potential acquisitions and integration of other companies; and other factors discussed in the “Risk Factors” section of Teknova’s most recent periodic reports filed with the Securities and Exchange Commission (“SEC”), including in Teknova’s Annual Report on Form 10-K for the year ended December 31, 2024, and subsequent Quarterly Reports on Form 10-Q filed with the SEC, all of which you may obtain for free on the SEC’s website at www.sec.gov. Although Teknova believes that the expectations reflected in its forward-looking statements are reasonable, Teknova does not know whether its expectations will prove correct. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, even if subsequently made available by Teknova on its website or otherwise. Teknova does not undertake any obligation to update, amend, or clarify these forward-looking statements, whether as a result of new information, future events, or otherwise, except as may be required under applicable securities laws.
Investor Contact
Matt Lowell
Chief Financial Officer
matt.lowell@teknova.com
+1 831-637-1100
Media Contact
Jennifer Henry
Senior Vice President, Marketing
jenn.henry@teknova.com
+1 831-313-1259
| ALPHA TEKNOVA, INC. | ||||||||||||||||
| Condensed Statements of Operations | ||||||||||||||||
| (Unaudited) | ||||||||||||||||
| (In thousands, except share and per share data) | ||||||||||||||||
| For the Three Months Ended June 30, | For the Six Months Ended June 30, | |||||||||||||||
| 2025 | 2024 | 2025 | 2024 | |||||||||||||
| Revenue | $ | 10,287 | $ | 9,614 | $ | 20,082 | $ | 18,904 | ||||||||
| Cost of sales | 6,303 | 6,810 | 13,091 | 13,891 | ||||||||||||
| Gross profit | 3,984 | 2,804 | 6,991 | 5,013 | ||||||||||||
| Operating expenses: | ||||||||||||||||
| Research and development | 581 | 678 | 1,133 | 1,538 | ||||||||||||
| Sales and marketing | 1,573 | 1,456 | 3,213 | 3,123 | ||||||||||||
| General and administrative | 4,929 | 5,483 | 10,421 | 12,864 | ||||||||||||
| Amortization of intangible assets | 287 | 287 | 574 | 574 | ||||||||||||
| Total operating expenses | 7,370 | 7,904 | 15,341 | 18,099 | ||||||||||||
| Loss from operations | (3,386 | ) | (5,100 | ) | (8,350 | ) | (13,086 | ) | ||||||||
| Other income (expenses), net | ||||||||||||||||
| Interest expense, net | (165 | ) | (272 | ) | (309 | ) | (417 | ) | ||||||||
| Other adjustment to loan exit fee | — | — | 485 | — | ||||||||||||
| Total other income (expenses), net | (165 | ) | (272 | ) | 176 | (417 | ) | |||||||||
| Loss before income taxes | (3,551 | ) | (5,372 | ) | (8,174 | ) | (13,503 | ) | ||||||||
| Provision for (benefit from) income taxes | 19 | (8 | ) | 41 | (42 | ) | ||||||||||
| Net loss | $ | (3,570 | ) | $ | (5,364 | ) | $ | (8,215 | ) | $ | (13,461 | ) | ||||
| Net loss per share—basic and diluted | $ | (0.07 | ) | $ | (0.13 | ) | $ | (0.15 | ) | $ | (0.33 | ) | ||||
| Weighted average shares used in computing net loss per share—basic and diluted | 53,448,736 | 40,853,882 | 53,435,210 | 40,829,383 | ||||||||||||
| ALPHA TEKNOVA, INC. | ||||||||
| Condensed Balance Sheets | ||||||||
| (Unaudited) | ||||||||
| (In thousands) | ||||||||
| As of June 30, | As of December 31, | |||||||
| 2025 | 2024 | |||||||
| ASSETS | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 3,276 | $ | 3,708 | ||||
| Short-term investments, held -to-maturity | 20,724 | 26,688 | ||||||
| Accounts receivable, net | 5,140 | 4,312 | ||||||
| Inventories, net | 7,610 | 6,801 | ||||||
| Prepaid expenses and other current assets | 1,307 | 1,267 | ||||||
| Total current assets | 38,057 | 42,776 | ||||||
| Property, plant, and equipment, net | 43,605 | 45,753 | ||||||
| Operating right-of-use lease assets | 14,960 | 15,767 | ||||||
| Intangible assets, net | 12,517 | 13,091 | ||||||
| Other non-current assets | 1,348 | 1,382 | ||||||
| Total assets | $ | 110,487 | $ | 118,769 | ||||
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | 1,204 | $ | 825 | ||||
| Accrued liabilities | 3,388 | 4,541 | ||||||
| Current portion of operating lease liabilities | 1,886 | 1,800 | ||||||
| Current portion of long-term debt | — | 4,045 | ||||||
| Total current liabilities | 6,478 | 11,211 | ||||||
| Deferred tax liabilities | 868 | 827 | ||||||
| Other accrued liabilities | — | 10 | ||||||
| Long-term debt, net | 13,032 | 9,443 | ||||||
| Long-term operating lease liabilities | 14,052 | 14,884 | ||||||
| Total liabilities | 34,430 | 36,375 | ||||||
| Stockholders’ equity: | ||||||||
| Preferred stock | — | — | ||||||
| Common stock | 1 | 1 | ||||||
| Additional paid-in capital | 202,802 | 200,924 | ||||||
| Accumulated deficit | (126,746 | ) | (118,531 | ) | ||||
| Total stockholders’ equity | 76,057 | 82,394 | ||||||
| Total liabilities and stockholders’ equity | $ | 110,487 | $ | 118,769 | ||||
| ALPHA TEKNOVA, INC. | ||||||||||||||||
| Condensed Statements of Cash Flows | ||||||||||||||||
| (Unaudited) | ||||||||||||||||
| (In thousands) | ||||||||||||||||
| For the Three Months Ended June 30, | For the Six Months Ended June 30, | |||||||||||||||
| 2025 | 2024 | 2025 | 2024 | |||||||||||||
| Operating activities: | ||||||||||||||||
| Net loss | $ | (3,570 | ) | $ | (5,364 | ) | $ | (8,215 | ) | $ | (13,461 | ) | ||||
| Adjustments to reconcile net loss to net cash used in operating activities: | ||||||||||||||||
| Bad debt expense | 4 | 49 | 49 | 56 | ||||||||||||
| Inventory reserve | 488 | 987 | 925 | 896 | ||||||||||||
| Depreciation and amortization | 1,590 | 1,626 | 3,170 | 3,262 | ||||||||||||
| Stock-based compensation | 950 | 833 | 1,802 | 2,140 | ||||||||||||
| Deferred taxes | 20 | (9 | ) | 41 | (44 | ) | ||||||||||
| Accrued interest income on short-term investments | 108 | — | 54 | — | ||||||||||||
| Amortization of discount on short-term investments | (171 | ) | — | (355 | ) | — | ||||||||||
| Amortization of debt financing costs | 43 | 104 | 129 | 188 | ||||||||||||
| Other adjustment to loan exit fee | — | — | (485 | ) | — | |||||||||||
| Non-cash lease expense | 31 | 47 | 61 | 94 | ||||||||||||
| Loss on disposal of property, plant, and equipment | 19 | — | 19 | 49 | ||||||||||||
| Changes in operating assets and liabilities: | ||||||||||||||||
| Accounts receivable | 472 | (86 | ) | (877 | ) | (705 | ) | |||||||||
| Inventories | (1,525 | ) | (767 | ) | (1,734 | ) | (289 | ) | ||||||||
| Prepaid expenses and other current assets | (36 | ) | 239 | (40 | ) | 413 | ||||||||||
| Other non-current assets | (29 | ) | 89 | 34 | 206 | |||||||||||
| Accounts payable | (360 | ) | (522 | ) | 380 | (389 | ) | |||||||||
| Accrued liabilities | (135 | ) | (40 | ) | (1,152 | ) | (1,764 | ) | ||||||||
| Other | — | (24 | ) | (10 | ) | (48 | ) | |||||||||
| Cash used in operating activities | (2,101 | ) | (2,838 | ) | (6,204 | ) | (9,396 | ) | ||||||||
| Investing activities: | ||||||||||||||||
| Purchases of short-term investments | (7,765 | ) | — | (9,735 | ) | — | ||||||||||
| Maturities of short-term investments | 10,000 | — | 16,000 | — | ||||||||||||
| Proceeds from sale of property, plant, and equipment | — | — | — | 125 | ||||||||||||
| Purchases of property, plant, and equipment | (207 | ) | (115 | ) | (413 | ) | (227 | ) | ||||||||
| Cash provided by (used in) investing activities | 2,028 | (115 | ) | 5,852 | (102 | ) | ||||||||||
| Financing activities: | ||||||||||||||||
| Proceeds from long-term debt | — | — | 1,110 | — | ||||||||||||
| Payment of exit fee costs | — | — | (1,110 | ) | — | |||||||||||
| Payments related to equity financing | — | — | — | (37 | ) | |||||||||||
| Repayment of financed insurance premiums | — | (103 | ) | (56 | ) | (409 | ) | |||||||||
| Proceeds from exercise of stock options | 16 | — | 20 | — | ||||||||||||
| Proceeds from issuance of common stock under employee stock purchase plan | 56 | 81 | 56 | 81 | ||||||||||||
| Payment of debt issuance costs | (100 | ) | (25 | ) | (100 | ) | (25 | ) | ||||||||
| Cash used in financing activities | (28 | ) | (47 | ) | (80 | ) | (390 | ) | ||||||||
| Change in cash and cash equivalents | (101 | ) | (3,000 | ) | (432 | ) | (9,888 | ) | ||||||||
| Cash and cash equivalents at beginning of period | 3,377 | 21,596 | 3,708 | 28,484 | ||||||||||||
| Cash and cash equivalents at end of period | $ | 3,276 | $ | 18,596 | $ | 3,276 | $ | 18,596 | ||||||||
| ALPHA TEKNOVA, INC. | ||||||||||||||||
| Reconciliation of Non-GAAP Measures to the Most Comparable GAAP Measures | ||||||||||||||||
| (Unaudited) | ||||||||||||||||
| (In thousands) | ||||||||||||||||
| For the Three Months Ended June 30, | For the Six Months Ended June 30, | |||||||||||||||
| 2025 | 2024 | 2025 | 2024 | |||||||||||||
| Net loss – as reported | $ | (3,570 | ) | $ | (5,364 | ) | $ | (8,215 | ) | $ | (13,461 | ) | ||||
| Add back: | ||||||||||||||||
| Interest expense, net | (165 | ) | (272 | ) | (309 | ) | (417 | ) | ||||||||
| Provision for (benefit from) income taxes | 19 | (8 | ) | 41 | (42 | ) | ||||||||||
| Depreciation expense | 1,303 | 1,339 | 2,596 | 2,688 | ||||||||||||
| Amortization of intangible assets | 287 | 287 | 574 | 574 | ||||||||||||
| EBITDA | $ | (1,796 | ) | $ | (3,474 | ) | $ | (4,695 | ) | $ | (9,824 | ) | ||||
| Other and non-recurring expenses: | ||||||||||||||||
| Stock-based compensation expense | 950 | 833 | 1,802 | 2,140 | ||||||||||||
| Severance pay and other termination benefits | — | — | — | 1,287 | ||||||||||||
| Other adjustment to loan exit fee | — | — | (485 | ) | — | |||||||||||
| Loss contingency | — | 73 | — | 73 | ||||||||||||
| Adjusted EBITDA | $ | (846 | ) | $ | (2,568 | ) | $ | (3,378 | ) | $ | (6,324 | ) | ||||
| For the Three Months Ended June 30, | For the Six Months Ended June 30, | |||||||||||||||
| 2025 | 2024 | 2025 | 2024 | |||||||||||||
| Cash used in operating activities | $ | (2,101 | ) | $ | (2,838 | ) | $ | (6,204 | ) | $ | (9,396 | ) | ||||
| Purchases of property, plant, and equipment | (207 | ) | (115 | ) | (413 | ) | (227 | ) | ||||||||
| Free Cash Flow | $ | (2,308 | ) | $ | (2,953 | ) | $ | (6,617 | ) | $ | (9,623 | ) | ||||
This press release was published by a CLEAR® Verified individual.
FAQ
What were Teknova's (TKNO) Q2 2025 earnings results?
What is Teknova's revenue guidance for 2025?
How did Teknova's Clinical Solutions segment perform in Q2 2025?
What is Teknova's current cash position and debt level?
How has Teknova's operating efficiency changed in Q2 2025?
